According to a recent LinkedIn post from Gestala, Founder & CEO Phoenix Peng participated in the Bank of America Breakthrough Technology Dialogue APAC in Singapore and gave an exclusive global interview on Bloomberg TV’s The China Show. The post indicates he discussed Gestala’s strategy following the closure of an RMB 150 million (US$21 million) angel funding round.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company’s LinkedIn post highlights that Gestala is developing an ultrasound-based brain-computer interface, which Peng described as an emerging niche within the broader BCI sector. The post notes that only a small number of new entrants have appeared globally in the past year, including Merge Labs, associated with OpenAI’s Sam Altman.
According to the post, Peng appears to frame these new BCI players as both peers and potential collaborators, underscoring a sector-wide focus on patient outcomes rather than solely on competition. For investors, this positioning may suggest a strategy that leverages partnerships and ecosystem development to accelerate technology validation and market adoption.
The disclosed angel funding size implies early but meaningful institutional or strategic backing for Gestala’s R&D-intensive business model. If the capital is deployed effectively, it could extend runway for clinical research, regulatory engagement, and prototype development, potentially improving the company’s prospects in a high-barrier, medtech-oriented segment.
The post also hints at rising institutional and media interest in the BCI space, given the Bank of America forum and Bloomberg TV coverage. Increased visibility may support Gestala’s ability to attract additional financing rounds and talent, though commercial timelines in neurotechnology remain long and regulatory and scientific risks substantial.